11 Results for "

RAD51-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "RAD51-IN-1" in MCE Product Catalog:

Cat. No.: HY-122705
CAS No.: 2101739-18-6
Purity:  99.89%
Target:  

RAD51

Research Areas:  

Cancer

RAD51-IN-1, a derivative of B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-R04608
Target:  

MicroRNA

Research Areas:  

Cancer

RAD51 SSDNA-1 is a chemically synthesized miRNA mimic that mimics endogenous miRNAs and upregulates miRNA activity for gain-of-function studies .
loading...
    loading...
Cat. No.: HY-115533
CAS No.: 1605301-58-3
Research Areas:  

Cancer

LBL1 is a Lamin A inhibitor with a Kd of 5.11 μM for LA (1-387). LBL1 directly binds to Lamin A and disrupts the Lamin A-Rad51 interaction, accelerates proteasome-mediated Rad51 degradation, and induces DNA double-strand breaks. LBL1 induces Apoptosis. LBL1 serves as a chemical tool for studying lamin biology and the post-translational regulation of Rad51. LBL1 can be used in studies related to breast cancer and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-162104
CAS No.: 2830213-53-9
Target:  

RAD51

Research Areas:  

Cancer

BRCA2-RAD51-IN-1 (Compound 46) is a BRCA2-RAD51 inhibitor with an EC50 value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .
loading...
    loading...
Cat. No.: HY-RS11606
Research Areas:  

Others

RAD51AP1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51AP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-169170
PARP1/BRD4-IN-3 (compound HF4) is a potent BRD4 and PARP1 inhibitor with IC50 values of 1210, 2019 nM for BRD4, PARP1, respectively. PARP1/BRD4-IN-3 shows antiproliferative activities. PARP1/BRD4-IN-3 induces apoptosis and cell cycle arrest at G0/G1 phase. PARP1/BRD4-IN-3 causes DNA damage and reduces the protein expression of Rad51. PARP1/BRD4-IN-3 shows antitumor efficacy .
loading...
    loading...
Cat. No.: HY-RS19559
Research Areas:  

Others

Rad51ap1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rad51ap1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS26055
Research Areas:  

Others

Rad51ap1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rad51ap1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-187096
Research Areas:  

Cancer

ERα/RAD51 degrader 1 is a ERα and RAD51 HyT degrader as well as an apoptosis (Apoptosis) inducer. ERα/RAD51 degrader 1 induces conformational changes in helices 11-12 of ERα, promotes the recruitment of Hsp70, and drives the degradation of ERα and RAD51 via the ubiquitin-proteasome pathway. ERα/RAD51 degrader 1 downregulates the expression of BRCA1/2. ERα/RAD51 degrader 1 acts on tamoxifen (HY-13757A)-sensitive and tamoxifen-resistant breast cancer in both in vitro and in vivo models. ERα/RAD51 degrader 1 is applicable to breast cancer-related research (hydrophobic tag: (HY-B0402)) .
loading...
    loading...
Cat. No.: HY-187621
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

ERα ligand 6 is an amino intermediate derived from OBHSA, and also serves as a precursor for the synthesis of ERα-targeted hydrophobic tag degraders, such as the ERα ligand moiety of ERα/RAD51 degrader 1 (HY-187096) .
loading...
    loading...
Cat. No.: HY-181842
Target:  

PARP ERK Apoptosis

Research Areas:  

Cancer

PARP1/ERK IN-1 is a dual PARP1/ERK inhibitor, with a PARP1 IC50 of 0.9 nM and an ERK2 IC50 of 1.8 nM. PARP1/ERK IN-1 inhibits proliferation and migration of various cancer cell lines, and induces apoptosis and DNA damage. PARP1/ERK IN-1 suppresses tumor growth in mouse models of colorectal cancer, and reduces the expression of Ki‑67, BRCA1 and Rad51. PARP1/ERK IN-1 can be used in the research of colorectal cancer, triple-negative breast cancer and pancreatic cancer .
loading...
    loading...
  • 1